App-Quantinova.ai

Identifying patients for clinical trials: Evaluation of NCI-designated community cancer centers.

Christine B. Mackay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Oncology education for internal medicine residents: The value of participating in a medical oncology rotation.

Nancy Alice Nixon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Trends in the content and format of main and optional consent forms in oncology clinical trials.

Sonja Rummell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The association between healthy days and patient-reported cancer symptoms in a metastatic cancer population.

Dana Drzayich Antol - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of acute-devoted departments (ADD) in cancer patients at the end of life in an Italian homogeneous area: Preliminary data.

Ilaria Panzini - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Assessment of practice patterns and quality indicators for lymphadenectomy in melanoma.

Robert John Feczko - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictors of readmission for hospitalized cancer patients: A cohort study.

Shiva Shrotriya - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

How cancer patients and oncologist assess data-sharing and the risk of re-identification in genomic research? Ethical implications for informed consent and governance.

Eva Caroline Winkler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Supportive oncology collaborative: Initial impact on supportive oncology screening and care across cancer centers.

Julia Rachel Trosman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Introducing first year medical students to oncology care through an elective seminar series.

Ryan Patrick McKillip - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Recognition of tumor lysis syndrome (TLS) risk and appropriateness of prophylaxis before and after adoption of a web broswer based risk assessment tool.

Jean Kerins - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development and pilot of brief surveys to evaluate the quality of coordinated, patient-centered cancer care.

Marcy Winget - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A prospective study to assess the effect of a discharge intervention on readmission rates in patients with a low Rothman Index score admitted to the inpatient oncology unit.

Tara Beth Sanft - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of published guidelines on chemotherapy dosing in overweight and obese patients in the adjuvant setting: A single institution experience.

Hassan Issa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of provider volume on outcomes of patients with Hodgkin lymphoma.

Catherine Gorman Ireland - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer.

Anne Wilkinson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochin hospital experience.

Pascaline Boudou-Rouquette - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Identifying advanced cancer patients readiness for goals of care conversations.

Cardinale B. Smith - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Quality and impact of eviQ Cancer Treatments Online: The medical oncologist's perspective.

Lydia PY. Loke - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of body mass index on chemotherapy-induced neutropenia in breast cancer.

Idris Yucel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts